Clinical trial
Karenitecin in Treating Patients With Recurrent Malignant Glioma
NCT00014521 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00014521 |
|---|---|
| Title | Karenitecin in Treating Patients With Recurrent Malignant Glioma |
| Official title | Phase I Evaluation Of The Safety Of Karenitecin In The Treatment Of Recurrent Malignant Gliomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | karenitecin |
| Start date | Jan 1, 2002 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 24, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: